Losartan
- Generic Name
- Losartan
- Brand Names
- Hyzaar, Cozaar
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23ClN6O
- CAS Number
- 114798-26-4
- Unique Ingredient Identifier
- JMS50MPO89
- Background
Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Los...
- Indication
Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hyper...
- Associated Conditions
- Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke
- Associated Therapies
- -
Coronavirus Response - Active Support for Hospitalised Covid-19 Patients
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Registration Number
- NCT04343001
- Locations
- 🇳🇬
University College Hospital, Ibadan, Oyo, Nigeria
🇵🇰Shifa Tameer-e-Millat University, Rawalpindi, Pakistan
Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- Sharp HealthCare
- Target Recruit Count
- 31
- Registration Number
- NCT04340557
- Locations
- 🇺🇸
Sharp Grossmont Hospital, La Mesa, California, United States
🇺🇸Sharp Chula Vista Medical Center, San Diego, California, United States
🇺🇸Sharp Memorial Hospital, San Diego, California, United States
Study of Open Label Losartan in COVID-19
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 34
- Registration Number
- NCT04335123
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Bassett Healthcare
- Target Recruit Count
- 15
- Registration Number
- NCT04328012
- Locations
- 🇺🇸
Bassett Medical Center, Cooperstown, New York, United States
Losartan for Patients With COVID-19 Requiring Hospitalization
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 205
- Registration Number
- NCT04312009
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸Hennepin County Medical Center, Minneapolis, Minnesota, United States
🇺🇸M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States
Losartan for Patients With COVID-19 Not Requiring Hospitalization
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 117
- Registration Number
- NCT04311177
- Locations
- 🇺🇸
Mayo Clinic Health System, Rochester, Minnesota, United States
🇺🇸Hennepin County Medical Center, Minneapolis, Minnesota, United States
🇺🇸M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States
Evaluation of Losartan and Perindopril in Blacks Type 2 Diabetics Patients
- Conditions
- Interventions
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Yaounde Central Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT04222686
- Locations
- 🇨🇲
Yaounde Central Hospital, NAtional Obesity Center, Yaounde, Cameroon
Losartan to Improve Hip Microfracture
- Conditions
- Interventions
- First Posted Date
- 2019-12-27
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Steadman Philippon Research Institute
- Target Recruit Count
- 1
- Registration Number
- NCT04212650
- Locations
- 🇺🇸
Steadman Philippon Research Institute, Vail, Colorado, United States
Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)
- Conditions
- Interventions
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 23
- Registration Number
- NCT04106856
- Locations
- 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia
- Conditions
- Interventions
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 145
- Registration Number
- NCT04074551
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Seoul-si, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.